- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.04. | IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA | 1 | Zacks | ||
| 17.04. | BTTR, ICCM and SXTC among pre-market losers | 3 | Seeking Alpha | ||
| 15.04. | IceCure submits final breast cancer cryoablation data to FDA | 1 | MassDevice | ||
| 15.04. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.04. | IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer | 70 | PR Newswire | Data presentation at highly influential American Society of Breast Surgeons ("ASBrS") Annual Meeting by Dr. Richard Fine wins Scientific Impact Award as voted by breast surgeons
President-Elect of... ► Artikel lesen | |
| 04.04. | IceCure Medical Ltd (ICCM) Q4 2023 Earnings Call Transcript | 1 | Insider Monkey | ||
| 04.04. | Earnings call: IceCure reports growth and FDA filings amid challenges | 1 | Investing.com | ||
| 03.04. | IceCure Medical reports FY results | 1 | Seeking Alpha | ||
| 03.04. | IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance | 65 | PR Newswire | Conference call to be held today at 10:00 am Eastern Time; Focus on U.S. market for ProSense® in breast cancer indication
CAESAREA, Israel, April 3, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq:... ► Artikel lesen | |
| 03.04. | IceCure Medical Ltd. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 02.04. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 19.03. | IceCure reports high success in breast cancer cryoablation study | 1 | Investing.com | ||
| 19.03. | IceCure Medical: ICE3 Cryoablation Breast Cancer Study Shows Positive Results | - | RTTNews | ||
| 19.03. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 19.03. | IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy | 65 | PR Newswire | Expects to submit full dataset to the FDA in April for marketing authorization of ProSense® for minimally invasive treatment of early-stage breast cancer
Study represents largest cryoablation study... ► Artikel lesen | |
| 12.03. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 12.03. | IceCure Medical: IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes | 92 | PR Newswire | Innovating as a global leader in cryoablation technologies, with 42 patents issued and allowed
Cryogenic flow control enhances the efficacy and precision of cryoablation procedures
CAESAREA, Israel... ► Artikel lesen | |
| 04.03. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 26.02. | IceCure gains on positive results from study in cancer patients | 2 | Reuters | ||
| 26.02. | IceCure reports full tumor reduction in breast cancer study | 2 | Investing.com |
Seite:
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORPEA | 13,436 | +0,60 % | ORPEA: emeis Sells a Real-Estate Portfolio in the Netherlands Worth a Total Value of Around €97 Million | Regulatory News:
ORPEA (Paris:ORP):
emeis announces that it has signed an agreement to sell a real estate portfolio of eleven nursing homes in the Netherlands to Bouwinvest for a total deed-in-hand... ► Artikel lesen | |
| NANO-X IMAGING | 9,345 | +1,14 % | Nano-X Imaging LTD.: Nanox Announces AI Software Increases Identification of Patients with Vertebral Compression Fractures, an early sign of Osteoporosis, Up to Six-Fold | - According to early findings in the ADOPT study, Nanox.AI software improves detection of key risk factor for osteoporosis, outperforming UK National Health Service national average - Findings... ► Artikel lesen | |
| BUTTERFLY NETWORK | 0,945 | +2,78 % | Butterfly Network Reports First Quarter 2024 Financial Results | BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with handheld, whole-body ultrasound... ► Artikel lesen | |
| GOODRX | 7,110 | +1,43 % | GoodRx Reports Fourth Quarter and Full Year 2023 Results | SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("GoodRx" or the "Company"), the leading destination for prescription savings in the U.S., has released its financial... ► Artikel lesen | |
| JOINT CORP | 16,120 | +25,35 % | Joint Corp reports results for the quarter ended in March - Earnings Summary | ||
| CARMAT | 3,090 | +0,49 % | CARMAT: Availability of the 2023 Universal Registration Document | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
| HYPERFINE | 0,800 | +1,70 % | Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results | GUILFORD, Conn., March 21, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable... ► Artikel lesen | |
| PROGYNY | 31,710 | -1,12 % | Progyny, Inc. Announces Third Quarter 2023 Results | Record Quarterly Revenue of $280.9 Million, Reflecting 37% Growth Over the Prior Year PeriodRaises Full Year Revenue and Earnings GuidanceStrong Sales Season Produces 1.3 Million New Covered Lives... ► Artikel lesen | |
| MIMEDX | 7,370 | -1,73 % | MiMedx Group, Inc: MIMEDX Announces First Quarter 2024 Operating and Financial Results | Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales Management... ► Artikel lesen | |
| BIOMERICA | 0,560 | -6,67 % | Biomerica jumps on signing multi-year distribution deal with major UAE healthcare company | ||
| ATRICURE | 20,890 | -5,99 % | AtriCure Reports First Quarter 2024 Financial Results | MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and... ► Artikel lesen | |
| ATRION | 384,00 | -3,03 % | Dividendenbekanntmachungen (14.03.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN PLC GB00BF8Q6K64 0,073 GBP 0,0853 EUR ABRDN PLC ADR US00108N1000 0,3203 USD 0,2925 EUR ACCO BRANDS CORPORATION US00081T1088 0... ► Artikel lesen | |
| TALKSPACE | 3,170 | +1,28 % | Talkspace to Report First Quarter 2024 and Host Conference Call | ||
| OUTSET MEDICAL | 3,140 | +4,67 % | Outset Medical Reports Fourth Quarter and Full Year 2023 Financial Results | SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) ("Outset" or the "Company"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity... ► Artikel lesen | |
| AMWELL | 0,573 | +10,17 % | American Well Corp reports results for the quarter ended in January - Earnings Summary |
ICECURE MEDICAL LTD gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von +0,010 (+0,85 %) liegt der Kurs bei 1,190 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
